In addition, the expression of Auxilins in CML patients in all three phases (CP-CML, accelerated phase, BC-CML and after remission of BC-CML patients) revealed that Auxilin-2 decreased, while Auxilin-1 increased across disease progression of CML patients (Fig. 1b). This evidence concerns the gene DNAJC6 and chronic myelogenous leukemia, BCR-ABL1 positive.